Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether β-cyclodextrin in rats

Journal of Pharmacy and Pharmacology

Volumn 52, Issue 8, 2000, Pages 911-917

  Tokihiro, K ^a   Arima, H ^a   Tajiri, S ^a   Irie, T ^a   Hirayama, F ^a   Uekama, K ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; IMMUNOREACTIVE INSULIN; INSULIN; MALTOSYL BETA CYCLODEXTRIN; SULPHOBUTYL ETHER BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CAPILLARY PERMEABILITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; ENZYME DEGRADATION; HYPOGLYCEMIA; MALE; NONHUMAN; RAT; SUBCUTANEOUS TISSUE;

EID: 0033817382     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357001774796     Document Type: Article

References (26)

1. Cyclodextrin derivatives in pharmaceutics
2. Absorption kinetics and biological effects of subcutaneously injected insulin preparations
3. Insulin pharmacokinetics
4. Pharmaceutical approach to subcutaneous dosage forms of insulin
5. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation
6. Cyclodextrins in peptide and protein delivery
7. Subcutaneous insulin absorption explained by insulin's physicochemical properties, evidence from absorption studies of soluble human insulin and insulin analogue in humans
8. The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic subjects
9. Fate of porcine and human insulin at the subcutaneous injection site. II. In-vitro degradation of insulins in the subcutaneous tissue of the rat
10. Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy
11. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs
12. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats
13. Protection afforded by maltosyl-β-cyclodextrin against α-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate
14. Fate of porcine and human insulin at the subcutaneous injection site. I. Degradation and absorption of insulin in the rat
15. Cyclodextrin inclusion compounds in research and industry
16. Lessons from the diabetes control and complications trials
17. Cyclodextrins: Their future in drug formulation and delivery
18. Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitor
19. Potential use of maltosyl-β-cyclodextrin for inhibition of insulin self-association in aqueous solution
20. Mass spectroscopic evidence on inhibiting effect of maltosyl-β-cyclodextrin on insulin self-association
21. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution
22. Cyclodextrins in drug carrier systems
23. Cyclodextrin drug carrier system
24. Some physicochemical properties of branched β-cyclodextrins and their inclusions characteristics